Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis
Important expansion of patent estate in the largest market for vaginal bacterial infections pHyph has shown superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Lund, Sweden, April 18, 2023. Swedish women’s health company Gedea Biotech announced…
Gedea Biotech appoints Anna-Karin Areskog as QA Director and receives ISO13485 certification
Lund, Sweden April 12, 2023: Gedea Biotech announces today that Anna-Karin Areskog has been appointed QA Director and that their ISO13485* re-certification has been approved. Both the announcement and the approved certification are important milestones for achieving CE marking for pHyph, the…
Gedea Biotech awarded SEK 3M from SWElife and MedTech4Health for groundbreaking antibiotic free women’s health trial
Impact on microbiome could be key to preventing vulvovaginal infection recurrence Lund, Sweden, April 4, 2023: Gedea Biotech today announced it has been awarded SEK 3M grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge…